What is the story about?
What's Happening?
TruDiagnostic has been awarded a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop its W-Function Epigenomic Roadmap. This next-generation model aims to map dynamic changes in DNA methylation to predict and prevent chronic diseases. The W-Function model introduces a systems-based approach, providing insights into disease onset, progression, and treatment response. By utilizing the world's largest longitudinal methylation dataset, TruDiagnostic seeks to identify causal epigenetic changes and improve predictive accuracy, offering more reliable health forecasts and new therapeutic targets.
Why It's Important?
The development of the W-Function Epigenomic Roadmap has the potential to transform precision health by shifting from reactive care to proactive, personalized health strategies. This model could improve early detection of chronic diseases such as cardiovascular disease and type 2 diabetes, guide personalized treatment plans, and accelerate drug discovery using actionable epigenetic markers. The grant highlights the importance of TruDiagnostic's mission to advance precision health and could lead to significant improvements in healthcare outcomes.
What's Next?
TruDiagnostic will focus its initial research on cardiovascular disease, type 2 diabetes, and mortality risk, with plans to expand applications across multiple chronic conditions. As the W-Function Epigenomic Roadmap is validated, it could become a key tool in personalized medicine, offering dynamic health tracking and guiding therapeutic interventions. The company may continue to collaborate with biotech developers, researchers, and academic institutions to further enhance the healthcare potential of epigenetic data.
AI Generated Content
Do you find this article useful?
